IP Verse

Anti-Cd20 Antibody - EP3507369

The patent EP3507369 was granted to Beijing Mabworks Biotech on Jun 12, 2024. The application was originally filed on Aug 28, 2017 under application number EP17845369A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3507369

BEIJING MABWORKS BIOTECH
Application Number
EP17845369A
Filing Date
Aug 28, 2017
Status
Granted And Under Opposition
May 10, 2024
Publication Date
Jun 12, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ARROWHOUSEMar 12, 2025VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE
KAROMar 11, 2025-ADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONCN20051064335
DESCRIPTIONUS5736137
DESCRIPTIONWO2016068799
INTERNATIONAL-SEARCH-REPORTCN104768581
INTERNATIONAL-SEARCH-REPORTCN104936985
INTERNATIONAL-SEARCH-REPORTCN105143270
INTERNATIONAL-SEARCH-REPORTCN105899535
OPPOSITIONCN107384932
OPPOSITIONCN107881160
OPPOSITIONEP3666891
OPPOSITIONWO03035835
OPPOSITIONWO2005044859
OPPOSITIONWO2014160490
OPPOSITIONWO2016068799
SEARCHWO2013013013
SEARCHWO2016068799

Non-Patent Literature (NPL) Citations (23) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN) ", WHO Drug Information, Recommended INN: List 65, (20110101), vol. 25, no. 1, pages 49 - 98, XP093266611
OPPOSITION- D16 - Annex I: Sequence alignment of the obinutuzumab amino acid sequences with the sequences of the patent
OPPOSITION- D27 - Annex II: Sequence alignment of the obinutuzumab amino acid sequences with the sequences of D5
OPPOSITION- D9 - Comparison of claims of 01 and 08
OPPOSITION- Dietmar Reusch, Tejada Max L, "Fc glycans of therapeutic antibodies as critical quality attributes (CQAs)", (20150930), URL: http://glycob.oxfordjournals.org/content/early/2015/08/10/glycob.cwv065.full.pdf, (20151001), XP055217432
OPPOSITION- FERRARA C. ET AL., "Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc[gamma]RIII and antibodies lacking core fucose", PROC. NATL. ACAD. SCI. USA, (20110802), vol. 108, no. 31, pages 12669 - 12674, XP002776038
OPPOSITION- Shantha Raju T., "Glycosylation Variations with Expression Systems and Their Impact on Biological Activity of Therapeutic Immunoglobulins", BioProcess Technical, (20030401), XP093266604
OPPOSITION- Umaña Pablo, Jean-Mairet Joël, Moudry Radmila, Amstutz Hanspeter, Bailey James E, "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity", (19990201), vol. 17, pages 176 - 180, XP093266608
OPPOSITION- Kah Fai Chan, Wahyu Shahreel, Corrine Wan, Gavin Teo, Noor Hayati, Shi Jie Tay, Wen Han Tong, Yuansheng Yang, Pauline M. Rudd, Peiqing Zhang, Zhiwei Song, "Inactivation of GDP-fucose transporter gene ( Slc35c1 ) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies", Biotechnology Journal, WILEY-VCH VERLAG, WEINHEIM, DE, DE , (20160301), vol. 11, no. 3, doi:10.1002/biot.201500331, ISSN 1860-6768, pages 399 - 414, XP055455163
OPPOSITION- Liming Liu, "Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins", Journal of pharmaceutical sciences, Elsevier Inc, Hoboken, Hoboken, (20150601), vol. 104, no. 6, doi:10.1002/jps.24444, ISSN 0022-3549, pages 1866 - 1884, XP055295176
OPPOSITION- Illidge Tim, Klein Christian, Sehn Laurie H., Davies Andrew, Salles Gilles, Cartron Guillaume, "Obinutuzumab in hematologic malignancies: Lessons learned to date", Cancer Treatment Reviews, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20151101), vol. 41, no. 9, doi:10.1016/j.ctrv.2015.07.003, ISSN 0305-7372, pages 784 - 792, XP093266610
OPPOSITION- SHINKAWA T, ET AL, "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20030131), vol. 278, no. 5, doi:10.1074/jbc.M210665200, ISSN 0021-9258, pages 3466 - 3473, XP002355427
OPPOSITION- P. Hossler, S. F Khattak, Z. J. Li, "Optimal and consistent protein glycosylation in mammalian cell culture", Glycobiology, Oxford University Press, (20090901), vol. 19, no. 9, doi:10.1093/glycob/cwp079, ISSN 09596658, pages 936 - 949, XP055112498
OPPOSITION- Peiqing Zhang et al., "Identification of functional elements of the GDP-fucose transporter SLC35C1 using a novel Chinese hamster ovary mutant", Glycobiology, (2012), vol. 22, doi:10.1093/glycob/cws064, XP055085542
OPPOSITION- Ekkehard Mössner et al., "Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity", Blood, (2010), vol. 115, doi:10.1182/blood-2009-06-225979, XP055190313
OPPOSITION- Golay J, Da Roit F, Bologna L, Ferrara C, Leusen J H, Rambaldi A, Klein C, Introna M., "Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY NLD, US, US , (20131114), vol. 122, no. 20, doi:10.1182/blood-2013-05-504043, ISSN 1528-0020, pages 3482 - 3491, XP002739744
OPPOSITION- OMASA TAKESHI ET AL, "Decrease in antithrombin III fucosylation by expressing GDP-fucose transporter siRNA in Chinese hamster ovary cells.", Journal of bioscience and bioengineering, ELSEVIER, AMSTERDAM, NL, NL , (20080801), vol. 106, no. 2, doi:10.1263/JBB.106.168, ISSN 1389-1723, pages 168 - 173, XP002504127
SEARCH- LIMING LIU, "Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins", JOURNAL OF PHARMACEUTICAL SCIENCES, US, (20150601), vol. 104, no. 6, doi:10.1002/jps.24444, ISSN 0022-3549, pages 1866 - 1884, XP055295176 [A] 1-12
SEARCH- HIGEL FABIAN ET AL, "N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, (20160113), vol. 100, doi:10.1016/J.EJPB.2016.01.005, ISSN 0939-6411, pages 94 - 100, XP029395648 [A] 1-12
SEARCH- SHIELDS ROBERT L ET AL, "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20020726), vol. 277, no. 30, doi:10.1074/JBC.M202069200, ISSN 0021-9258, pages 26733 - 26740, XP002442140 [A] 1-12
SEARCH- DIETMAR REUSCH ET AL, "Fc glycans of therapeutic antibodies as critical quality attributes", GLYCOBIOLOGY, US, (20150811), vol. 25, no. 12, doi:10.1093/glycob/cwv065, ISSN 0959-6658, pages 1325 - 1334, XP055425665 [A] 1-12
SEARCH- TAKAHIRO ISHIGURO ET AL, "A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients", CANCER SCIENCE, JP, (20100805), vol. 101, no. 10, doi:10.1111/j.1349-7006.2010.01663.x, ISSN 1347-9032, pages 2227 - 2233, XP055670588 [A] 1-12
SEARCH- E. MOSSNER ET AL, "Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity", BLOOD, (20100603), vol. 115, no. 22, doi:10.1182/blood-2009-06-225979, ISSN 0006-4971, pages 4393 - 4402, XP055190313 [A] 1-12

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents